Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity.
Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity.
复制标题
eculizumab是抗PR特异性严重的冷凝集素疾病中免疫抑制治疗的桥梁。
DOI：
10.1002/ccr3.399
复制
发表时间：
2015-11
影响因子：
0.7
通讯作者：
Lam S
中科院分区：
文献类型：
--
作者：
Shapiro R;Chin-Yee I;Lam S
血液动力学受损的严重冷凝集素疾病需要迅速稳定自身免疫性溶血性贫血，以此作为利妥昔单抗免疫抑制作用的桥梁。在此，我们描述了Eulizumab治疗一例严重的补体介导的溶血患者，该患者的血液动力学状态恶化，尽管进行了支持性输血和治疗性血浆置换。
Severe cold agglutinin disease with hemodynamic compromise requires rapid stabilization of the autoimmune hemolytic anemia as a bridge to the immunosuppressive effect of rituximab. Herein, we describe eculizumab treatment of severe complement-mediated hemolysis in a patient whose hemodynamic status deteriorated in spite of supportive blood transfusions and therapeutic plasma exchange.